TrialAn Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Trial details
- Registry ID
- NCT05022901
- Phase
- Phase 3
Drug research
Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity has not yet been verified against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular MelanomaNCT05022901 | DCTH | Phase 3 | Active not recruiting | 2024-03-01Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |